<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8170">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818804</url>
  </required_header>
  <id_info>
    <org_study_id>N-20120076</org_study_id>
    <nct_id>NCT01818804</nct_id>
  </id_info>
  <brief_title>The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis</brief_title>
  <official_title>The Effect of n-3 Polyunsaturated Fatty Acids on Risk Markers for Cardiovascular Disease and Inflammation in Patients With Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg Universityhospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg Universityhospital</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory
      diseases . Recent evidence suggest that psoriatic arthritis is also associated with an
      increased cardiovascular risk with accelerated atherosclerosis and increased cardiovascular
      risk. However, data regarding cardiovascular comorbidity and cardiovascular risk factors in
      patients with psoriatic arthritis are limited.

      Objective: The aim of this study is to investigate the effect of daily supplementation with
      3 g n-3 polyunsaturated fatty acids on risk markers for cardiovascular disease and
      inflammation in patients with psoriatic arthritis.

      Design: Randomized double-blind, placebo-controlled, multicenter trial with n-3
      polyunsaturated fatty acids in patient with psoriatic arthritis.

      Setting: Departments of Rheumatology, Nephrology and Cardiology at Aalborg University
      Hospital and Vendsyssel Hospital in Region Northern Denmark

      Participants: 156 men and women aged &gt; 18 years with psoriatic arthritis classified by the
      CASPAR criteria will be included. Exclusion criteria: cardiac arrhythmias, conduction
      disturbances, treatment with biological drugs or oral corticosteroids. Inclusion time:
      spring 2013 to spring 2015.

      Method: The following data will be collected for each participant: Interview including
      dietary records, assessment of tender and swollen joints, enthesitis, dactylitis, patient
      global assessment of disease activity (Visual Analogue Scale ), global assessment of pain
      (Visual Analogue Scale), psoriatic skin involvement by Psoriatic Area and Severity Index
      (PASI), laboratory parameters of disease activity and risk markers of cardiovascular
      disease.

      For detection of early cardiovascular risk markers Heart Rate Variability (HRV) and Pulse
      Wave Velocity (PWV) will be performed.

      Main outcome measures: The primary endpoint will be HRV and secondary endpoints will be PWV,
      inflammatory activity and use of analgesics.

      The trial is approved by The local Ethics Committee, registration number N20120076
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in HRV measure</measure>
    <time_frame>Baseline and 24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heart Rate Velocity, non-invasive measurement for the autonom regulation of the heart associated with risk of cardiovascular disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PWV</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pulse wave Velocity, non-invasive measurement for arterioscleroses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Inflammation parameters</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease activity score for psoriatic arthritis, Psoriasis area severity index, enthesitis score, CRP</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>n-3PUFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>n-3 polyunsaturated fattyacids from fish oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olive oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olive oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>n-3PUFA</intervention_name>
    <arm_group_label>n-3PUFA</arm_group_label>
    <other_name>n-3 polyunsaturated fattyacids from fishoil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>olive oil</intervention_name>
    <arm_group_label>olive oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged &gt; 18 years with

          -  Psoriatic arthritis classified by the CASPAR criteria

          -  written informed consent

        Exclusion Criteria:

          -  Treatment with biological drugs

          -  Treatment with oral corticosteroids

          -  cardiac arrhythmias
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salome Kristensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Universityhospital, Department og Rheumatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeppe H Christensen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Aalborg University Hospital, Department of Nephrology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salome Kristensen, MD</last_name>
    <phone>+ 45 99 32 81 83</phone>
    <email>sakr@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeppe H Christensen, Professor</last_name>
    <phone>+ 45 99 32 66 30</phone>
    <email>Jeppe.hagstrup.christensen@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital, Department of Rheumatology</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salome Kristensen, MD</last_name>
      <phone>+ 45 99 32 81 83</phone>
      <email>sakr@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Jeppe H Christensen, MD professor</last_name>
      <phone>+ 45 99 32 66 30</phone>
      <email>jeppe.hagstrup.christensen@rn.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Salome Kristensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vendsyssel Hospital in Region Northern Denmark, Department of Rheumatology</name>
      <address>
        <city>Hj√∏rring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salome Kristensen, MD</last_name>
      <phone>+ 45 99 32 81 83</phone>
      <email>sakr@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Claus Rasmussen, MD</last_name>
      <phone>+ 45 97 64 16 51</phone>
      <email>clara@rn.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Salome Kristensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 9, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg Universityhospital</investigator_affiliation>
    <investigator_full_name>Salome Kristensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
